معرفی
Professor John Cleland is a leading academic in cardiovascular medicine at the University of Glasgow, specializing in cardiac diseases with a focus on heart failure, iron deficiency, and metabolic health. He holds a professorial position in the Department of Cardiovascular & Metabolic Health within the College of Medical, Veterinary and Life Sciences.
His research spans multiple areas including cardiac resynchronization therapy, biomarker analysis, and clinical trial design. Key collaborations involve groups such as the Heart Failure Association and the BIOSTAT-CHF consortium. Cleland has contributed to landmark trials like IRONMAN (evaluating iron therapy in heart failure) and RESHAPE-HF (mitral regurgitation interventions).
Research interests prominently feature heart failure pathophysiology, iron deficiency management, and the interplay between diabetes and cardiovascular outcomes. His work integrates clinical practice with translational research, emphasizing evidence-based guidelines and cost-effectiveness analyses.
Notable contributions include over 600 publications (as of 2025) in high-impact journals such as *European Journal of Heart Failure* and *Circulation*. His studies often address practical clinical questions like optimal diuretic use, biomarker utilization, and device therapies.
Grants and funding sources are not explicitly listed, but his involvement in multinational trials suggests significant external support. He leads the Glasgow Heart Failure Centre, fostering multidisciplinary teams focused on translational cardiac research.